Avalon Pharma Signs Strategic Agreement with Adalvo for Obesity Treatments

Middle East Pharmaceuticals Industries Company, Avalon Pharma, is pleased to announce the signing of a contract with Adalvo Limited, a global pharmaceutical company headquartered in Malta, to secure the rights for the registration and marketing of their GLP 1 products for the treatment of weight loss and obesity.

Key Highlights:

-Product Scope - GLP-1 agonists for the treatment of chronic obesity and weight loss.
-Contract Duration - 7 years.
-Contract Value - EUR 3 million initial agreement fee.
-Future Prospects - Potential expansion to additional GLP products and opportunities for local manufacturing.

Riyadh, 4th August 2025 – Middle East Pharmaceutical Industries Company (Avalon Pharma)
is pleased to announce the signing of a landmark agreement with Adalvo Limited, a global
pharmaceutical company headquartered in Malta. The agreement grants Avalon Pharma exclusive
rights to register, market, and distribute Adalvo’s GLP-1 products targeting chronic obesity and
weight loss in selected markets across the Middle East and North Africa, including exclusive rights
for the Kingdom of Saudi Arabia.
This agreement marks a major step forward in Avalon Pharma’s mission to bring innovative and
impactful healthcare solutions to the region. Regulatory submissions will be prepared in accordance
with the requirements of the Saudi Food and Drug Authority (SFDA) and respective regulatory
bodies in other MENA countries prior to commercial launch.
As the Company looks further ahead, a key aspect to this agreement includes provisions for
expanding to other GLP products and the potential for localized manufacturing.

Mr. Mohamed Maher Al Ghannam, Managing Director and CEO of Avalon Pharma,
commented, “At Avalon Pharma, the well-being of our patients and the communities
we serve remains our top priority. This partnership with Adalvo allows us to introduce
groundbreaking therapies that have the potential to significantly improve health
outcomes across the region. By expanding access to innovative treatments in a high
growth therapeutic area, we are taking an important step toward addressing community
demand in line with our commitment to healthcare excellence.”
Mr. Al Ghannam added, “This collaboration is also a strategic milestone for Avalon Pharma.
Adalvo’s GLP-1 portfolio aligns strongly with our vision to diversify our offerings, launch
in dynamic, fast-growing segments, and drive innovation through both local expertise
and global partnerships. Furthermore, supporting access to transformative medicines
directly contributes to Saudi Arabia’s Vision 2030 and our mission of delivering
meaningful, sustainable healthcare solutions.”